EUVIMEDEUVIMED entdecken
Klinische Studie

Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia

Guiping Liao, Dongmei Liu, Beibei Yang, Zhili Geng, Changqing Wei, Manlv Wei, Changyu Yang iD, Yanni Xie, Lina Lu, Yali Zhou, Xiaolin Yin iD

Pediatric Blood & Cancer · 2026-10 · 73 (10)

DOI: 10.1002/1545-5017.70563 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 23.07.2026. Verfasst von Guiping Liao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, 923rd Hospital of the Joint Logistics Support Force, Nanning, China. Hauptthemen laut MEDLINE: Transplantation Conditioning, Hematopoietic Stem Cell Transplantation, beta-Thalassemia, Myeloablative Agonists. Die Arbeit nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Graft failure and transplant‐related mortality remain major barriers to haploidentical donor hematopoietic stem cell transplantation (HID‐HSCT) in children and adolescents aged ≥7 years with transfusion‐dependent thalassemia (TDT). Thus, a novel low‐toxicity myeloablative conditioning regimen was developed to improve transplantation outcomes.

Methods

In this prospective, single‐center study (clinical trial registration ChiCTR2300071890), TDT patients aged ≥7 years were enrolled to evaluate the safety and efficacy of a conditioning regimen comprising fludarabine, busulfan, thiotepa, and melphalan (F‐BMT). For HID recipients, graft‐versus‐host disease (GVHD) prophylaxis included half‐dose PTCY combined with the in vivo T‐cell depletion (porcine anti‐human lymphocyte immunoglobulin or rabbit anti‐human thymocyte globulin), along with other immunosuppressive agents. The primary endpoint was the 2‐year thalassemia‐free survival (TFS) rate.

Results

From June 2023 to August 2024, 29 TDT patients aged ≥7 years undergoing HID‐HSCT were enrolled (14 males, 15 females). The 2‐year TFS and overall survival rates were both 93.1%. Neutrophil and platelet engraftment were achieved in all patients, with no reported graft failure. The observed incidence of Grade II–IV acute GVHD was 17.2%. Chronic GVHD occurred in 6.9% of the patients. Regimen‐related toxicities were manageable, with only one case of sinusoidal obstruction syndrome and three cases of hemorrhagic cystitis, all of which resolved with supportive treatment. No mixed chimerism was observed.

Conclusions

The F‐BMT regimen provides effective myeloablation with reduced toxicity, supporting its feasibility for HID‐HSCT in TDT patients aged ≥7 years.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transplantation ConditioningHematopoietic Stem Cell Transplantationbeta-ThalassemiaMyeloablative AgonistsTransplantation, HaploidenticalHumansFemaleThiotepaAdolescentMaleBusulfanVidarabineChildMelphalanProspective StudiesGraft vs Host DiseaseSurvival RateFollow-Up StudiesBlood TransfusionPrognosis

Stichwörter der Autor:innen

conditioning regimenhaploidentical donorhematopoietic stem cell transplantationtransfusion‐dependent thalassemia

Substanzen

ThiotepafludarabineBusulfanVidarabineMelphalanMyeloablative Agonists

Autor:innen und Institutionen

  • Department of Hematology, 923rd Hospital of the Joint Logistics Support Force, Nanning, China.

ORCID-Profile: Changyu Yang, Xiaolin Yin

Zitieren

APA

Liao, G., Liu, D., Yang, B., Geng, Z., Wei, C., Wei, M., Yang, C., Xie, Y., Lu, L., Zhou, Y., & Yin, X. (2026). Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70563

Vancouver

Liao G, Liu D, Yang B, Geng Z, Wei C, Wei M, et al. Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70563

BibTeX
@article{Liao2026,
  author = {Liao, Guiping and Liu, Dongmei and Yang, Beibei and Geng, Zhili and Wei, Changqing and Wei, Manlv and Yang, Changyu and Xie, Yanni and Lu, Lina and Zhou, Yali and Yin, Xiaolin},
  title = {Fludarabine, Busulfan, Thiotepa, and Melphalan: A Novel Low‐Toxicity Myeloablative Conditioning Regimen for Haploidentical HSCT in Children and Adolescents Aged ≥7 Years With Transfusion‐Dependent β‐Thalassemia},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {10},
  doi = {10.1002/1545-5017.70563}
}
Kostenlos starten →